Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer

Radiotherapy and Oncology

Volumn 103, Issue 1, 2012, Pages 69-75

  Mortensen, Hanna R ^a   Overgaard, Jens ^a   Specht, Lena ^b   Overgaard, Marie ^a   Johansen, Jørgen ^c   Evensen, Jan F ^d   Andersen, Lisbeth J ^e   Andersen, Elo ^f   Grau, Cai ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Department of Oncology ^*  (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Accelerated radiotherapy; Head and neck cancer; Radiotherapy; Side effects

Indexed keywords

ANALGESIC AGENT; OPIATE DERIVATIVE;

ADULT; AGED; AGEUSIA; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG USE; DYSPHAGIA; FEMALE; FIBROSIS; HEAD AND NECK CARCINOMA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUCOSA INFLAMMATION; MULTICENTER STUDY; PAIN; PREVALENCE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORBIDITY; PREVALENCE; RADIOTHERAPY;

EID: 84859730424     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2012.01.002     Document Type: Article

References (35)

1. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-54. (Pubitemid 44292807)
2. Denham JW, Peters LJ, Johansen J, et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol 1999;52:157-64. (Pubitemid 29461083)
3. Scott-Brown M, Miah A, Harrington K, Nutting C. Evidence-based review: quality of life following head and neck intensity-modulated radiotherapy. Radiother Oncol 2010;97:249-57.
4. Bentzen SM, Vaeth M, Pedersen DE, Overgaard J. Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now! Int J Radiat Oncol Biol Phys 1995;32:1531-4.
5. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933-40. (Pubitemid 37159288)
6. Overgaard J, Mohanti BK, Begum N, et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol 2010;11:553-60.
7. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-8. (Pubitemid 39524916)
8. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94. (Pubitemid 32322245)
9. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-21. (Pubitemid 27345198)
10. Skladowski K, Maciejewski B, Golen M, et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys 2006;66:706-13. (Pubitemid 44436685)
11. Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36. (Pubitemid 27345199)
12. Bourhis J, Lapeyre M, Tortochaux J, et al. Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial. Radiother Oncol 2011;100:56-61.
13. Zackrisson B, Nilsson P, Kjellen E, et al. Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma - The ARTSCAN study. Radiother Oncol 2011;100:41-8.
14. Suwinski R, Bankowska-Wozniak M, Majewski W, et al. Randomized clinical trial on continuous 7-days-a-week postoperative radiotherapy for high-risk squamous cell head-and-neck cancer: a report on acute normal tissue reactions. Radiother Oncol 2005;77:58-64. (Pubitemid 41503390)
15. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16. (Pubitemid 30488207)
16. Jackson SM, Weir LM, Hay JH, Tsang VH, Durham JS. A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997;43:39-46. (Pubitemid 27191977)
17. Bentzen SM, Saunders MI, Dische S, Bond SJ. Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial. Radiother Oncol 2001;60:123-35. (Pubitemid 32601965)
18. Bentzen SM, Dorr W, Anscher MS, et al. Normal tissue effects: reporting and analysis. Semin Radiat Oncol 2003;13:189-202. (Pubitemid 36962643)
19. Dische S, Warburton MF, Jones D, Lartigau E. The recording of morbidity related to radiotherapy. Radiother Oncol 1989;16:103-8. (Pubitemid 19258948)
20. Dische S. The uniform reporting of treatment-related morbidity. Semin Radiat Oncol 1994;4:112-8. (Pubitemid 24116949)
21. Hjelm-Hansen M, Jorgensen K, Andersen AP, Lund C. Laryngeal carcinoma. II. Analysis of treatment results using the Ellis model. Acta Radiol Oncol Radiat Phys Biol 1979;18:385-407. (Pubitemid 10214448)
22. Jensen K, Bonde JA, Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. Radiother Oncol 2006;78:298-305.
23. Wygoda A, Maciejewski B, Skladowski K, et al. Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with conventional and accelerated irradiation. Int J Radiat Oncol Biol Phys 2009;73:384-90.
24. Hartley A, Sanghera P, Kazi W, et al. Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck cancer. Clin Oncol (R Coll Radiol) 2011;23:29-33.
25. Fowler JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol 2003;69:161-8. (Pubitemid 37485875)
26. Bourhis J, Lapeyre M, Tortochaux J, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. J Clin Oncol 2006;24:2873-8. (Pubitemid 46630588)
27. Saunders MI, Rojas AM, Parmar MK, Dische S. Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010;77:3-8.
28. Li Y, Taylor JM, Ten Haken RK, Eisbruch A. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 2007;67:660-9. (Pubitemid 46215864)
29. Braam PM, Roesink JM, Moerland MA, Raaijmakers CP, Schipper M, Terhaard CH. Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:659-64. (Pubitemid 40779751)
30. Messmer MB, Thomsen A, Kirste S, Becker G, Momm F. Xerostomia after radiotherapy in the head & neck area: long-term observations. Radiother Oncol 2011;98:48-50.
31. Shaker R, Easterling C, Kern M, et al. Rehabilitation of swallowing by exercise in tube-fed patients with pharyngeal dysphagia secondary to abnormal UES opening. Gastroenterology 2002;122:1314-21. (Pubitemid 34465174)
32. Bhide SA, Gulliford S, Fowler J, et al. Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. Radiother Oncol 2010;97:86-91.
33. Jones B. Normal and abnormal swallowing: imaging in diagnosis and therapy; chapter 5: adaptation, compensation and decompensation. New York: Springer-Verlag; 2003. p. 83-90.
34. Langsenlehner T, Renner W, Gerger A, et al. Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients. Radiother Oncol 2011;98:387-93.
35. Pratesi N, Mangoni M, Mancini I, et al. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol 2011;99:356-61.